BioLine Rx
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 79
- Market Cap
- $59.2M
- Website
- http://www.biolinerx.com
- Introduction
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
Clinical Trials
31
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- Drug: 2 mg/kg BL-8040Drug: BL-8040-matching placeboDrug: 400 mg Moxifloxacin (1x400 mg tablet)Drug: 1.25 mg/kg BL-8040 + BL-8040-matching placebo
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT05293171
- Locations
- 🇺🇸
Celerion, Phoenix, Arizona, United States
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- Interventions
- Drug: BL-8040 1.25 mg/kg + G-CSFDrug: Placebo +G-CSF
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT03246529
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT03154827
- Locations
- 🇺🇸
The University of Texas - Md Anderson Cancer Center - Leukemia Center, Houston, Texas, United States
🇺🇸Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States
🇨🇿Fakultni Nemocnice Brno / University Hospital Brno Interni Hematologicka A Onkologicka Klinika / Internal Hematology and Oncology Clinic, Brno, Czechia
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT02826486
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Honor Health, Scottsdale, Arizona, United States
🇺🇸Ochsner Medical Center, New Orleans, Louisiana, United States
Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome
- Conditions
- Aplastic AnemiaHypoplastic Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT02462252
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
BioLineRx Reports Promising Pancreatic Cancer Trial Results with 64% Response Rate for Motixafortide Combination
BioLineRx's CheMo4METPANC Phase 2 pilot study demonstrated a 64% overall response rate and 91% disease control rate in first-line pancreatic cancer patients treated with motixafortide combination therapy.
Sickle Cell Disease Pipeline Shows Robust Growth with 60+ Therapies in Development Across Multiple Clinical Phases
DelveInsight's 2025 assessment reveals a robust sickle cell disease pipeline with 55+ companies developing 60+ therapeutic candidates across various clinical development stages.
Genentech Advances RO-7759065 Development for Metastatic Solid Tumors
• Genentech USA is developing RO-7759065, a novel parenteral treatment targeting metastatic solid tumors, expanding their robust oncology pipeline. • The drug candidate is undergoing clinical evaluation with GlobalData tracking its phase transition and likelihood of approval based on 18 years of historical drug development data. • Genentech, a Roche subsidiary, brings significant expertise in oncology drug development, supported by partnerships with BioLineRx, Charles River Laboratories, and Amunix.
BioLineRx's APHEXDA Gains Momentum in Stem Cell Mobilization for Multiple Myeloma
BioLineRx's APHEXDA (motixafortide) receives FDA approval for stem cell mobilization in multiple myeloma patients, marking a significant advancement in over a decade.